These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32282767)

  • 1. Alteration of Transforming Growth Factor β Signaling Pathway Predicts Worse Prognosis in Pancreatic Ductal Adenocarcinoma.
    Li M; Li A; Zhao X; Hou S; Lu S; Mou Y; Liu X; Cai S; Cao D; Tian B
    Pancreas; 2020 Apr; 49(4):534-542. PubMed ID: 32282767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
    Javle M; Li Y; Tan D; Dong X; Chang P; Kar S; Li D
    PLoS One; 2014; 9(1):e85942. PubMed ID: 24465802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological and prognostic significance of ubiquitin-specific peptidase 15 and its relationship with transforming growth factor-β receptors in patients with pancreatic ductal adenocarcinoma.
    Jiang B; Zhou L; Lu J; Wang Y; Liu C; Liang Z; Zhou W; You L; Guo J
    J Gastroenterol Hepatol; 2021 Feb; 36(2):507-515. PubMed ID: 32875609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kindlin-2 induced by TGF-β signaling promotes pancreatic ductal adenocarcinoma progression through downregulation of transcriptional factor HOXB9.
    Zhan J; Song J; Wang P; Chi X; Wang Y; Guo Y; Fang W; Zhang H
    Cancer Lett; 2015 May; 361(1):75-85. PubMed ID: 25724625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
    Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
    BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrophage-derived exosomal microRNA-501-3p promotes progression of pancreatic ductal adenocarcinoma through the TGFBR3-mediated TGF-β signaling pathway.
    Yin Z; Ma T; Huang B; Lin L; Zhou Y; Yan J; Zou Y; Chen S
    J Exp Clin Cancer Res; 2019 Jul; 38(1):310. PubMed ID: 31307515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAp73 loss favors Smad-independent TGF-β signaling that drives EMT in pancreatic ductal adenocarcinoma.
    Thakur AK; Nigri J; Lac S; Leca J; Bressy C; Berthezene P; Bartholin L; Chan P; Calvo E; Iovanna JL; Vasseur S; Guillaumond F; Tomasini R
    Cell Death Differ; 2016 Aug; 23(8):1358-70. PubMed ID: 26943320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis.
    Dal Molin M; Zhang M; de Wilde RF; Ottenhof NA; Rezaee N; Wolfgang CL; Blackford A; Vogelstein B; Kinzler KW; Papadopoulos N; Hruban RH; Maitra A; Wood LD
    Clin Cancer Res; 2015 Apr; 21(8):1944-50. PubMed ID: 25623214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma.
    Qian ZR; Rubinson DA; Nowak JA; Morales-Oyarvide V; Dunne RF; Kozak MM; Welch MW; Brais LK; Da Silva A; Li T; Li W; Masuda A; Yang J; Shi Y; Gu M; Masugi Y; Bui J; Zellers CL; Yuan C; Babic A; Khalaf N; Aguirre A; Ng K; Miksad RA; Bullock AJ; Chang DT; Tseng JF; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Thorner AR; Ducar M; Wollison B; Laing A; Hahn WC; Meyerson M; Fuchs CS; Ogino S; Hornick JL; Hezel AF; Koong AC; Wolpin BM
    JAMA Oncol; 2018 Mar; 4(3):e173420. PubMed ID: 29098284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transposon mutagenesis identifies candidate genes that cooperate with loss of transforming growth factor-beta signaling in mouse intestinal neoplasms.
    Morris SM; Davison J; Carter KT; O'Leary RM; Trobridge P; Knoblaugh SE; Myeroff LL; Markowitz SD; Brett BT; Scheetz TE; Dupuy AJ; Starr TK; Grady WM
    Int J Cancer; 2017 Feb; 140(4):853-863. PubMed ID: 27790711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
    Goggins M; Shekher M; Turnacioglu K; Yeo CJ; Hruban RH; Kern SE
    Cancer Res; 1998 Dec; 58(23):5329-32. PubMed ID: 9850059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low frequency of KRAS mutation in pancreatic ductal adenocarcinomas in Korean patients and its prognostic value.
    Kwon MJ; Jeon JY; Park HR; Nam ES; Cho SJ; Shin HS; Kwon JH; Kim JS; Han B; Kim DH; Choi YL
    Pancreas; 2015 Apr; 44(3):484-92. PubMed ID: 25513781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
    Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
    Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
    Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.